ArticlePLoS genetics2025
The insulin-like peptide INS-27 mediates a muscle-to-neuron feedback signal coupling muscle activity with AMPA receptor trafficking.
Article in PLoS genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Axon termination of the SAB motor neurons inbioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Regulation of AMPA Receptor (AMPAR) levels at synapses controls synaptic strength and is a major mechanism underlying learning and memory. Growing evidence indicates that AMPAR trafficking can be regulated by extracellular factors. Here, we show that the insulin-like peptide INS-27 mediates a muscle-to-neuron signal that promotes surface levels of the C. elegans AMPAR GLR-1 at synapses in pre-motor AVA interneurons that reside two synaptic layers upstream of the neuromuscular junction. Mutants lacking cholinergic neuromuscular signaling or muscle activity trigger an increase in surface GLR-1 levels in upstream AVA neurons. Genetic data suggest that this signal is dependent on the dense-core vesicle regulator unc-31/CAPS, the insulin-like peptide INS-27, which is one of the most highly expressed neuropeptides in muscle, and the Insulin/IGF-1 receptor DAF-2. ins-27 loss-of-function mutants exhibit decreased surface GLR-1 levels and defects in glutamatergic behavior. Further, loss of neuromuscular junction signaling stimulates secretion of INS-27 from muscle in an unc-31/CAPS-dependent manner. Our data support a model in which INS-27 is released from muscle and signals via DAF-2/Insulin/IGF-1 receptors to promote surface levels of GLR-1 in AVA neurons. Our study reveals a potential feedback signal that couples muscle activity with surface AMPARs in upstream neurons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.